Page 36 - Bio Developments News Today

A booster shot of Moderna’s COVID-19 vaccine increases neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels, according to data released by the company today.

A single booster dose of Sanofi and GSK’s recombinant adjuvanted COVID-19 vaccine candidate delivered ‘consistently strong immune responses’, according to data released by the companies.

Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.

Oxford Biomedica plc has announced an extended commercial supply agreement with Novartis for the manufacture of lentiviral vectors for several Novartis CAR-T products.

Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.

Cincinnati Children's Hospital Medical Center and research service provider CTI Clinical Trial & Consulting Services will form a company to provide cell and gene therapy manufacturing services to the biotech and pharmaceutical industries.

Catalent is reporting that the technology transfer for the manufacture of BrainStorm Cell Therapeutics’ autologous cellular therapy at its facility in Houston, Texas has been finalized.

Two doses of the Pfizer/BioNTech vaccine ‘may not be sufficient’ to protect against infection with the Omicron variant; but three doses of the vaccine neutralize the variant, according to a preliminary laboratory study released by the companies.

Medicago and GSK’s plant-based COVID-19 vaccine candidate has reported an overall efficacy rate of 71% in Phase 3 trials: with the final regulatory submission for the vaccine to be filed with Health Canada shortly.

Trince, a spin-off of Ghent University (UGent) that is focused on advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo, has raised €4m (US$4.5m) from investors.